Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosutinib versus imatinib in newly diagnosed chronic phase chronic myelogenous leukemia
NL-OMON44373Phase 3Active, not recruiting
- Sponsor
- Avillion Development 1
- Start
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic myelogenous leukemia (CML) comparing Bosutinib arm with Imatinib arm (2 arms). Primary endpoint: Major molecular response at 12 months. Started Nov 2014; status: active, not recruiting.
02
Drugs
bosutinibimatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON44373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44373.